Johnson & Johnson (JNJ)
154.22
-1.44 (-0.93%)
NYSE · Last Trade: May 11th, 1:17 AM EDT
Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.
Via Benzinga · May 9, 2025
The company said that 66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational oral Icotrokinra achieved site-specific clear or almost clear skin at week 16.
Via Stocktwits · May 9, 2025
Before Kenvue and Johnson & Johnson, Ruh was at PepsiCo for 17 years.
Via Stocktwits · May 8, 2025
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
Via Benzinga · May 8, 2025
Marjorie Taylor Greene disclosed buying more than 50 stocks in early May. A look at the list and why the congresswoman's past trades have drawn red flags.
Via Benzinga · May 7, 2025
Via Benzinga · May 7, 2025
FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.
Via Benzinga · May 6, 2025
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new tariffs on imported medicines within two weeks
Via Benzinga · May 6, 2025
FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases.
Via Benzinga · May 5, 2025
Trump claims he might personally phone CEOs for business moves he dislikes, using this tactic on Amazon's Bezos over tariff disclosures.
Via Benzinga · May 5, 2025
Why JOHNSON & JOHNSON (NYSE:JNJ) provides a good dividend, while having solid fundamentals.
Via Chartmill · May 5, 2025
Via The Motley Fool · May 5, 2025
Via The Motley Fool · May 4, 2025
We are tracking a potential major bottom forming in Primary wave 2. A clear five-wave move into wave {i} suggests the early stages of an upside trend resumption.
Via Talk Markets · May 2, 2025
Via Benzinga · May 1, 2025
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year?
Via Investor's Business Daily · May 1, 2025
Trump to highlight investments from top companies, including Nvidia, J&J, and Toyota, in 'Investing in America' event to mark first 100 days in office.
Via Benzinga · April 29, 2025
A lawsuit claims Eli Lilly, Johnson & Johnson, and Kaiser Permanente failed to warn consumers about breast cancer risks linked to their antipsychotic drugs Risperdal and Zyprexa.
Via Benzinga · April 28, 2025
Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.
Via Benzinga · April 28, 2025
See these three stocks that are among the most important in their industries, which have announced sizable increases in their dividends.
Via MarketBeat · April 28, 2025
The companies are working on treatments for a form of bladder cancer.
Via Investor's Business Daily · April 28, 2025
See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.
Via MarketBeat · April 28, 2025